Chronic non-communicable diseases — including hypertension, heart failure with preserved ejection fraction (HFpEF), chronic kidney disease, type 2 diabetes, vascular cognitive impairment, and atherosclerosis — share common risk factors, clinical clustering, and progressive vascular remodeling. This review synthesizes evidence demonstrating that these conditions arise from a single upstream process: loss of vascular coherence driven by mitochondrial redox stress, endothelial nitric oxide (NO) depletion, glycocalyx and exclusion-zone (EZ) water layer disruption, and resulting arterial–microvascular impedance mismatch.
In early disease, excess mitochondrial reactive oxygen species oxidize tetrahydrobiopterin (BH₄), uncoupling endothelial nitric oxide synthase and reducing NO bioavailability. This biochemical shift initiates glycocalyx thinning, loss of structured near-wall water, and mechanotransduction switching from KLF2/KLF4-mediated laminar-shear protection to Piezo1/RhoA/ROCK/YAP–TAZ–driven pro-inflammatory states. The outcome is arterial stiffening (decreased compliance) and microvascular rarefaction (increased resistance), producing LC resonance failure, increased pulsatile energy transmission, impaired perfusion reserve, and organ injury that manifests in predictable patterns across the heart, kidney, brain, retina, and skeletal muscle.
Importantly, the early biochemical and microvascular phases are highly reversible, while structural macrovascular changes can be functionally compensated through resonance retuning. Therapeutic emphasis should shift from blood pressure reduction alone to restoring vascular coherence via redox rebalancing, eNOS recoupling, glycocalyx repair, microvascular recruitment, and ventricular–arterial phase matching.
This framework unifies diverse cardiometabolic diseases under a single mechanistic model and provides targeted strategies for prevention, early intervention, and phenotype reversal.










